Actavis, Inc.
Records under this name other than patents Actavis, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,959,946 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,785,627 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Term ended Jul 31, 2026 · From the USPTO record | Term ended | Term ended Jul 31, 2026 | From the USPTO record |
| US 9,060,941 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Term ended Ended no later than Mar 11, 2025 · Low confidence | Term ended | Ended no later than Mar 11, 2025 | Low confidence |
| US 8,470,368 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Term ended Nov 1, 2023 · From the USPTO record | Term ended | Term ended Nov 1, 2023 | From the USPTO record |
| US 8,309,125 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Ended no later than Sep 19, 2023 · From the USPTO record | Term ended | Ended no later than Sep 19, 2023 | From the USPTO record |
| US 8,668,931 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative Formerly held Term ended Ended no later than Sep 19, 2023 · From the USPTO record | Term ended | Ended no later than Sep 19, 2023 | From the USPTO record |
| US 8,551,516 | Administration of non-oral androgenic steroids to women Formerly held Term ended Term ended Aug 31, 2022 · From the USPTO record | Term ended | Term ended Aug 31, 2022 | From the USPTO record |
| US 6,630,166 | Compositions for conjugated estrogens and associated methods Formerly held Term ended Term ended Feb 12, 2022 · From the USPTO record | Term ended | Term ended Feb 12, 2022 | From the USPTO record |
| US 8,597,683 | Modified release tranexamic acid formulation Formerly held Lapsed on the fee record Ended Dec 3, 2021 · From the USPTO record | Lapsed on the fee record | Ended Dec 3, 2021 | From the USPTO record |
| US 9,387,178 | Modified release tranexamic acid formulation Formerly held Lapsed on the fee record Ended Jul 12, 2020 · From the USPTO record | Lapsed on the fee record | Ended Jul 12, 2020 | From the USPTO record |